TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06682715

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whey protein
Description: 10 out of 20 participants will be randomly added in this group after initial consent in which they will be fully informed about all benefits, risks, and discomforts of this investigation. Screening process will include (1) subjects of age 18-30 years of age; (2) subjects should be free of any recent history of illnesses, musculoskeletal problems, and metabolic diseases; (3) are not using any supplements and medications; and (5) participated in ≥5 training sessions/week.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrin
Description: 10 out of 20 participants will be randomly added in this group after initial consent in which they will be fully informed about all benefits, risks, and discomforts of this investigation. Screening process will include (1) subjects of age 18-30 years of age; (2) subjects should be free of any recent history of illnesses, musculoskeletal problems, and metabolic diseases; (3) are not using any supplements and medications; and (5) participated in ≥5 training sessions/week.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: nutrition education
Description: Nutrition for sports knowledge questionnaire will be used to assess the pre-nutrition education and post-nutrition education knowledge of athletes. Nutrition education will be given using evidence based nutrition education hand-outs and one-on-one counselling for each athlete in which they will be guided about sources of high biological value protein sources to meet daily protein requirement. Dietary intake will be monitored using 3 day food record method during 2-6 weeks of supplementation. Food logs will be filled out by participants during each weeks to monitor their protein intake. Three food logs (2 weekdays \[Mon-Thurs/Tue-Fri\] and 1 weekend day \[Sat/Sun\]) will be submitted by each subject every week.
Study: NCT05302557

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ileostomy stimulation
Description: Daily stimulation of the efferent loop will be performed during the two weeks prior to the surgery.
Study: NCT05663866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Montelukast will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib tablets will be administered orally.
Study: NCT04840602

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow biopsy and aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow biopsy and aspiration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy and aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy and aspiration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibrutinib
Description: Given PO

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT05626088

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study: NCT06592989

Intervention type: DRUG
Intervention: sorafenib, gefitinib
Description: Sofantinib: 250mg, QD, oral; Gefitinib: 250mg, QD, oral.
Study: NCT05043012

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: flexible AIR coil
Description: mpMRI scan

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endorectal coi
Description: mpMRI scan
Study: NCT06657222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TUB-030
Description: A complete treatment cycle is defined as 21 calendar days. TUB-030 will be administered as an intravenous (IV) solution on day 1 of each treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TUB-030
Description: A complete treatment cycle is defined as 21 calendar days. TUB-030 will be administered as an intravenous (IV) solution on day 1 of each treatment cycle
Study: NCT06592794

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1403
Description: Intramuscular (IM) injection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride solution by IM injection.
Study: NCT06605118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Injection
Description: 500mg azithromycin in 250 mL of normal saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 250 mL of normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care Preoperative antibiotics
Description: standard of care preoperative antibiotics (excluding azithromycin) prior to incision

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care Preoperative antibiotics
Description: standard of care preoperative antibiotics (excluding azithromycin) prior to incision
Study: NCT05091853

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Adhesix mesh
Description: 2 meshes are used; the self-gripping Progrip mesh and the self-adhesive Adhesix mesh

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Adhesix mesh
Description: 2 meshes are used; the self-gripping Progrip mesh and the self-adhesive Adhesix mesh
Study: NCT06604520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Individuals with bvFTD and mood symptoms will receive approximately 12 weeks of treatment with vortioxetine
Study: NCT06590402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine, Dexamethasone in Adductor Canal Block
Description: 0.25% 15-20ml bupivacaine (local anesthestic) delivered as part of the adductor canal block with 2 mg preservative-free dexamethasone (corticosteroid) delivered as part of the adductor canal block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine, Dexamethasone in Adductor Canal Block
Description: 0.25% 15-20ml bupivacaine (local anesthestic) delivered as part of the adductor canal block with 2 mg preservative-free dexamethasone (corticosteroid) delivered as part of the adductor canal block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine, Dexamethasone in Anterior Femoral Cutaneous Nerve Block
Description: 10 ml of 0.25% bupivacaine (local anesthetic) delivered as part of the anterior femoral cutaneous nerve block with 2 mg preservative-free dexamethasone (corticosteroid) delivered as part of the anterior femoral cutaneous nerve block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine, Dexamethasone in Anterior Femoral Cutaneous Nerve Block
Description: 10 ml of 0.25% bupivacaine (local anesthetic) delivered as part of the anterior femoral cutaneous nerve block with 2 mg preservative-free dexamethasone (corticosteroid) delivered as part of the anterior femoral cutaneous nerve block
Study: NCT06669182

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Theta-Burst Transcranial Magnetic Stimulation
Description: 50Hz, stimulation intensity of 100% RMT, duration of 40s as a group of stimulation, 600 stimulation pulses, repeated stimulation of bilateral cerebellar dentate nuclei, with a 5-minute interval between each group, 1200 stimulation pulses per site, 5 times a week, treatment for 4 weeks, then treat once a week for 8 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Intermittent Theta-Burst Transcranial Magnetic Stimulation
Description: 50Hz, stimulation intensity of 100% RMT, duration of 40s as a group of stimulation, 600 stimulation pulses, repeated stimulation of bilateral cerebellar dentate nuclei, with a 5-minute interval between each group, 1200 stimulation pulses per site, 5 times a week, treatment for 4 weeks, then treat once a week for 8 weeks.
Study: NCT06011551

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The ReGelTec HYDRAFIL™ System
Description: The ReGelTec HYDRAFIL System is designed to deliver an injectable hydrogel implant (the HYDRAFIL implant) for the treatment of a degenerative lumbar disc.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conservative Care Management
Description: Conservative care management (including physical therapy and/or pain medication)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservative Care Management
Description: Conservative care management (including physical therapy and/or pain medication)
Study: NCT05351476

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: 300 Kcal worth of weight lifting, 3 times/week for 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance Exercise
Description: 300 Kcal worth of treadmill walking, 3 times/week for 12 weeks
Study: NCT06586255

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concurrent Immunotherapy and Radiation Therapy
Description: Radiation therapy will begin between 12 to 18 weeks from the start of adjuvant nivolumab. Patients will receive radiation therapy for about 6 weeks.
Study: NCT06598540

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kindness-focused
Description: This mindset intervention frames food choices as an opportunity to practice self-kindness. Individuals randomized to this arm will participate in a 15-20-minute live virtual educational session delivered via the Stanford Zoom platform. The recording of the session will be available for 7 days on a private and secure educational web-based platform. After participating in the initial educational session, participants will have the option to engage in brief (less than 10-minute) web-based activities on their own time during weeks 2 and 5. Examples of such activities include sharing their experiences about considering food choices as an act of self-kindness with other study participants or writing an encouraging letter to a study participant and physician colleague through the private and secure message board of a web-based educational platform.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health-focused
Description: Brief education intervention framing food choices as a component of a healthy lifestyle. Individuals randomized to this arm will participate in a 15-20-minute live virtual educational session. The recording of the session will be available for 7 days on a private and secure educational web-based platform. After participating in the initial educational session, participants will have the option to engage in brief (less than 10-minute) web-based activities on their own time during weeks 2 and 5. Examples of such activities include writing a brief statement about their perspective on the usefulness of healthy eating and sharing it with physician colleagues in their group through the private and secure message board of a web-based educational platform.
Study: NCT05572515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: Teclistamab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide will be administered orally.
Study: NCT06682715

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutrition education
Description: Nutrition for sports knowledge questionnaire will be used to assess the pre-nutrition education and post-nutrition education knowledge of athletes. Nutrition education will be given using evidence based nutrition education hand-outs and one-on-one counselling for each athlete in which they will be guided about sources of high biological value protein sources to meet daily protein requirement. Dietary intake will be monitored using 3 day food record method during 2-6 weeks of supplementation. Food logs will be filled out by participants during each weeks to monitor their protein intake. Three food logs (2 weekdays \[Mon-Thurs/Tue-Fri\] and 1 weekend day \[Sat/Sun\]) will be submitted by each subject every week.
Study: NCT05761561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and medical nutrition
Description: The study dietitian and exercise trainer will each conduct weekly counseling sessions via telephone or zoom throughout the course of chemotherapy (approximately 18 weeks) to assist the participants in achieving the diet and exercise study goals. Participants will be provided written informational material, exercise bands for strength training and a Fitbit to record activity.~Participant goals are to: 1) participate in 150 min/week of moderate-intensity physical activity 2) participate in two weekly strength training sessions; 3) eat a combination of 5 or more servings of vegetables and/or fruits per day 4) consume 25 grams or more of fiber/day; 5) consume adequate amounts of protein to prevent muscle wasting (1.2g/kg body weight).
Study: NCT05572515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered orally in PVd and intravenously or orally in Kd.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib will be administered intravenously.
Study: NCT06667076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy: Pemetrexed
Description: Pemetrexed will be administered through IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy: Carboplatin
Description: Carboplatin will be administered through IV infusion.
Study: NCT04568967

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Concentrated urine with Xpert Ultra
Description: Molecular TB diagnostic test on urine

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Stool with Xpert Ultra
Description: Molecular TB diagnostic test on stool
Study: NCT06613529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: online mindfulness training
Description: Use publicly available online mindfulness training resources. The training content was to guide patients to practice mindfulness techniques, including where the body is, the mind is and relaxation learning.
Study: NCT06614218

Intervention type: DEVICE
Intervention: Minimally Invasive Micro Sclerostomy
Description: The MIMS® procedure uses the proprietary MIMS® device, which creates a sclerostomy in the eye.
Study: NCT05112939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV LA
Description: RPV LA will be administered at different formulations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV LA
Description: RPV LA will be administered at different formulations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV LA
Description: RPV LA will be administered at different formulations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV LA
Description: RPV LA will be administered at different formulations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV LA
Description: RPV LA will be administered at different formulations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAB LA
Description: CAB LA will be administered at formulation 3.
Study: NCT06610981

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Description: Laser acupuncture will be used in this study with energy of 4 J per point for 80 s, with a total dosage of 24 J in each session, 2 times /week for 4 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional physical therapy
Description: exercise program consisted of stretching for hamstring, gastrocnemius and iliotibial band, and strengthening exercises, which include isometric quadriceps exercises, straight leg raising, lateral straight leg raise, isometric hip adduction and squat to 30° knee flexion, 2 times /week for 4 weeks

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: traditional physical therapy
Description: exercise program consisted of stretching for hamstring, gastrocnemius and iliotibial band, and strengthening exercises, which include isometric quadriceps exercises, straight leg raising, lateral straight leg raise, isometric hip adduction and squat to 30° knee flexion, 2 times /week for 4 weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham laser acupuncture
Description: Participants will receive laser acupuncture while the device is turned off.
Study: NCT06673706

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Front-of-package label
Description: Participants will see packaged food-and-beverage items displayed with labels as specified by their assigned group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Front-of-package label
Description: Participants will see packaged food-and-beverage items displayed with labels as specified by their assigned group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Front-of-package label
Description: Participants will see packaged food-and-beverage items displayed with labels as specified by their assigned group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Front-of-package label
Description: Participants will see packaged food-and-beverage items displayed with labels as specified by their assigned group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Front-of-package label
Description: Participants will see packaged food-and-beverage items displayed with labels as specified by their assigned group
Study: NCT06619483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3018250 Dose 1
Description: Single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to BAY3018250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3018250 Dose 2
Description: Single dose
Study: NCT06622785

Intervention type: BEHAVIORAL
Intervention: Physical activity
Description: Data were collected using a International Physical Activity Questionnaire-Short Form (IPAQ-SF)

Intervention type: BEHAVIORAL
Intervention: Physical activity
Description: Data were collected using a International Physical Activity Questionnaire-Short Form (IPAQ-SF)
Study: NCT05325489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized Budesonide
Description: use 0.5mg/2ml Pulmicort Respules BIS QD and oral montelukast sodium chewable tablets 4mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Budesonide Spray
Description: nasal spray 100μg QD and oral montelukast sodium chewable tablets 4mg QD
Study: NCT05412290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Mosunetuzumab is administered intravenously in a step-up dosing strategy. The doses will be 1 mg on C1D1, 2 mg on C1D8, 60 mg on C1D15, 60 mg on C2D1, and 30 mg for all doses following.
Study: NCT06622785

Intervention type: BEHAVIORAL
Intervention: Physical activity
Description: Data were collected using a International Physical Activity Questionnaire-Short Form (IPAQ-SF)

Intervention type: BEHAVIORAL
Intervention: Exercise Benefits
Description: Data were collected using a Exercise Benefits/Barriers Scale .

Intervention type: BEHAVIORAL
Intervention: Exercise Benefits
Description: Data were collected using a Exercise Benefits/Barriers Scale .

Intervention type: BEHAVIORAL
Intervention: Exercise Benefits
Description: Data were collected using a Exercise Benefits/Barriers Scale .
Study: NCT06127797

Intervention type: BEHAVIORAL
Intervention: Questionnaire/Interview
Description: Participation on this study will be over as soon as you complete the questionnaire/interview after your scheduled scans.
Study: NCT06624384

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 1 drug
Description: Group 1: In this group, the aim is to compare 2 drugs, cyclosporine 0.05% and Lifitgrast . In one eye, cyclosporine 0.05% eye drops are randomly poured and in the opposite eye, Lifitgrast eye drops are poured.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 2: Drug and placebo
Description: Group 2: In this group, the aim is to compare 2 drugs, cyclosporine 0.05% and Artelac artificial tear as a placebo. In one eye, cyclosporine 0.05% eye drops are randomly poured, and in the opposite eye, Artelac artificial tear are poured.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 3: Drug and palcebo
Description: Group 3: In this group, the aim is to compare 2 drugs, Lifitgrast and Artelac artificial tear as a placebo. In one eye, Lifitgrast eye drops are randomly poured, and in the opposite eye, Artelac artificial tear are poured.
Study: NCT06625840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1167
Description: Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1167
Description: Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Administration
Study: NCT06625658

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: clear aligner group
Description: aligner group change aligner every10 day
Study: NCT06625489

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part A: Placebo
Description: Placebo will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Nintedanib will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Nintedanib will be administered.